← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Stratatech Corporation
Hazelwood, WI
$28,285,849
Total funding
25
Grants
Funding over time
peak $5.2M · FY2005–16$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$24,373,039 · 21
DOD$3,263,550 · 2
NSF$649,260 · 2
By mechanism
R44$19,668,583 · 7
—$3,912,810 · 4
R42$3,278,577 · 3
R43$967,890 · 8
R41$279,662 · 2
N43$178,327 · 1
Investigators at Stratatech Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Clinical Trial of Antimicrobial Skin to treat Diabetic Ulcers$1,931,207
R44 · FY2012 · DK
PRECLINICAL DEVELOPMENT OF EPIREADY, A NOVEL THERAPEUTIC TO TREAT NONHEALING DIABETIC FOOT ULCERS$1,698,207
· FY2016 · Department of the Army
BIOLOGICAL ACTIVE ADVANCED ANTIMICROBIAL HUMAN SKIN SUBSTITUTE FOR THE TREATMENT OF COMBAT WOUNDS$1,565,343
· FY2012 · Department of Defense
A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce$1,281,128
R44 · FY2011 · DK
Clinical Evaluation of StrataGraft Skin Tissue$1,226,250
R44 · FY2005 · AR
Clinical Trial of Antimicrobial Skin to treat Diabetic Ulcers$1,049,455
R44 · FY2013 · DK
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$1,000,000
R44 · FY2011 · AI
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$980,388
R44 · FY2012 · AI
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo$978,425
R44 · FY2013 · AI
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$872,419
R44 · FY2008 · DK
Tissue-Based Cytokine Immunotherapy for Skin Cancer$841,868
R44 · FY2011 · CA
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$796,845
R44 · FY2007 · DK
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$761,545
R44 · FY2006 · DK
A Human Intraepithelial Tumor Microenvironment Assay$614,540
R42 · FY2010 · CA
Enhancing the Vascularization Properties of Skin Tissue$608,811
R44 · FY2007 · AG
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$563,553
R44 · FY2004 · DK
A Human Intraepithelial Tumor Microenvironment Assay$550,042
R42 · FY2011 · CA
Enhancing the Vascularization Properties of Skin Tissue$536,289
R44 · FY2009 · AG
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*$530,835
R44 · FY2005 · DK
Expression of Angiogenic Growth Factors in Keratinocytes$514,391
R44 · FY2003 · GM